1. Home
  2. MLYS vs ARCT Comparison

MLYS vs ARCT Comparison

Compare MLYS & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$23.61

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Arcturus Therapeutics Holdings Inc.

ARCT

Arcturus Therapeutics Holdings Inc.

HOLD

Current Price

$6.69

Market Cap

189.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
ARCT
Founded
2019
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
189.9M
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
MLYS
ARCT
Price
$23.61
$6.69
Analyst Decision
Strong Buy
Buy
Analyst Count
6
11
Target Price
$48.67
$27.70
AVG Volume (30 Days)
1.1M
464.2K
Earning Date
03-12-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
37.43
20.00
EPS
N/A
N/A
Revenue
N/A
$82,031,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.44
$5.85
52 Week High
$47.65
$24.14

Technical Indicators

Market Signals
Indicator
MLYS
ARCT
Relative Strength Index (RSI) 36.30 42.90
Support Level $12.98 $6.36
Resistance Level $31.09 $7.88
Average True Range (ATR) 1.56 0.37
MACD -0.06 -0.00
Stochastic Oscillator 12.94 22.60

Price Performance

Historical Comparison
MLYS
ARCT

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About ARCT Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

Share on Social Networks: